Researchers Detail Favorable Zevalin Data At ASH, But Also Medicare Concern

ATLANTA - No sooner did Medicare announce it will cap funding for two approved radioimmunotherapies than an international phase III trial is reporting that one of them, Zevalin, can prolong progression-free survival by two years in relapsed follicular non-Hodgkin's lymphoma